Deploy a successful NGS testing
service with Omicia’s Opal Clinical™
variant interpretation and reporting platform

Accurately report on causative variants from
gene panels, exomes, and whole genomes

Omicia’s Opal Clinical™ system is a robust, scalable platform
developed in collaboration with leading testing labs to accelerate
the clinical interpretation of NGS data.

Learn how your lab can optimize report turnaround time and increase diagnostic yield with NGS testing. Schedule a free Opal demo today.

Schedule a Demo

Explore Opal Clinical

Multiple NGS Testing Analysis Options

Opal Clinical’s robust functionality allows labs to deploy and interpret clinical tests on targeted gene panels, single exome and family exome tests.

Labs can launch condition-specific panels with established reimbursement such as: BRCA1/2; Illumina TruSight and Ion AmpliSeq ready-to-use panels; and custom gene panels.

Learn more »

Standardized Variant Interpretation 

Opal Clinical’s intuitive interface and automated annotations enable labs to interpret NGS genomic data faster and with unprecedented accuracy.

Optimized for clinical testing labs, users can deploy standardized workflows to quickly identify and confirm already classified variants, and efficiently evaluate novel or unclassified variants.

Learn more »

Seamless Integration with Lab Workflow

From sample accession and CPT code assignment to LIS integration and EMR output, Opal Clinical facilitates rapid report turnaround.

Our CLIA and HIPAA-compliant platform produces physician-ready reports, seamlessly integrates into any lab’s workflow, and can interface with your LIS to ensure the fidelity of patient information and test results.

Learn more »

Omicia’s Opal NGS informatics, interpretation, and reporting platform provides labs with the key capabilities
to enable the application of genomics to routine diagnostics and personalized therapies.

Flexible. Expand your NGS test menu.

Get started with targeted gene panels and deliver accurate, more comprehensive results faster than competing labs.  Opal Clinical ensures that efficient NGS testing workflows can be set up quickly, enabling you to easily augment your panel test menu as well as single and family exome tests.

Scalable. Manage increasing testing volumes.

Develop and validate a standardized interpretation workflow to ensure accurate, consistent, and rapid reporting.  Opal Clinical’s bioinformatics pipeline enables your lab to scale its testing volume to meet the increasing demands of ordering physicians, without investing additional resources.

 

Accurate. Increase your diagnostic yield.

Leverage Omicia’s advanced algorithms to speed and significantly improve causative variant discovery.  Opal powers the interpretation of single patient and family-based diagnostic analyses including challenging clinical scenarios involving novel disease genes or atypical phenotypes.

Versatile. Accelerate targeted drug development.

Identify genomic signatures of interest to assess disease risk and drug response using interactive analysis tools.  Opal Clinical Trials’ comprehensive annotations and advanced algorithms complement every stage of the drug development process, from biomarker discovery to trial stratification and patient screening.

Learn how your lab can launch NGS-based diagnostic testing with Opal Clinical.

Schedule a Demo Explore Opal Clinical

Pioneers in genomics, diagnostics, and bioinformatics

Omicia’s leaders have proven track records, including senior roles on the Human Genome Project, at LabCorp, Merck, and Life Technologies.

We’ve built the Opal platform to deliver genomics-based solutions that expedite diagnoses, improve medical outcomes, and accelerate understanding of the genetic basis of disease.  Meet our leaders >

Omicia executives

Trusted by leaders in translational and clinical omics

Over 500 research, pharma, and clinical diagnostics labs rely on Omicia’s technological precision and clinical expertise.

Omicia’s algorithms have been developed in the lab, designed for the clinic, and have been validated in dozens of published research and clinical studies.  Read our publications >

Over 300 translational research and clinical institutions trust Omicia's products

Automated, Algorithmic Approaches to Variant Interpretation
Omicia Blog. June 10, 2015

Digital DNA on blue background_190x134

When Disease Strikes from Nowhere
Nature 513, 445–448. September 18, 2014

Omicia in the News: When Disease Strikes from Nowhere. Nature, 2014